-DOCSTART- -X- O
Existing -X- _ O
and -X- _ O
emerging -X- _ O
viral -X- _ O
CNS -X- _ B-Patient
infections -X- _ I-Patient
are -X- _ O
major -X- _ O
sources -X- _ O
of -X- _ O
human -X- _ O
morbidity -X- _ O
and -X- _ O
mortality. -X- _ O
Treatments -X- _ O
of -X- _ O
proven -X- _ O
efficacy -X- _ O
are -X- _ O
currently -X- _ O
limited -X- _ O
predominantly -X- _ O
to -X- _ O
herpesviruses -X- _ O
and -X- _ O
human -X- _ O
immunodeficiency -X- _ O
virus. -X- _ O
Development -X- _ O
of -X- _ O
new -X- _ O
therapies -X- _ O
has -X- _ O
been -X- _ O
hampered -X- _ O
by -X- _ O
the -X- _ O
lack -X- _ O
of -X- _ O
appropriate -X- _ O
animal -X- _ O
model -X- _ O
systems -X- _ O
for -X- _ O
some -X- _ O
important -X- _ O
viruses -X- _ O
and -X- _ O
by -X- _ O
the -X- _ O
difficulty -X- _ O
in -X- _ O
conducting -X- _ O
human -X- _ O
clinical -X- _ O
trials -X- _ O
for -X- _ O
diseases -X- _ O
that -X- _ O
may -X- _ O
be -X- _ O
rare -X- _ O
, -X- _ O
or -X- _ O
in -X- _ O
the -X- _ O
case -X- _ O
of -X- _ O
arboviral -X- _ O
infections -X- _ O
, -X- _ O
often -X- _ O
have -X- _ O
variable -X- _ O
seasonal -X- _ O
and -X- _ O
geographic -X- _ O
incidence. -X- _ O
Nonetheless -X- _ O
, -X- _ O
many -X- _ O
novel -X- _ O
approaches -X- _ O
to -X- _ O
antiviral -X- _ O
therapy -X- _ O
are -X- _ O
available -X- _ O
including -X- _ O
candidate -X- _ O
thiazolide -X- _ B-Intervention
and -X- _ I-Intervention
purazinecarboxamide -X- _ I-Intervention
derivatives -X- _ I-Intervention
with -X- _ O
potential -X- _ O
broad-spectrum -X- _ O
antiviral -X- _ O
efficacy. -X- _ O
New -X- _ O
herpesvirus -X- _ O
drugs -X- _ O
include -X- _ O
viral -X- _ B-Intervention
helicase-primase -X- _ I-Intervention
and -X- _ I-Intervention
terminase -X- _ I-Intervention
inhibitors. -X- _ I-Intervention
The -X- _ O
use -X- _ O
of -X- _ O
antisense -X- _ O
oligonucleotides -X- _ O
and -X- _ O
other -X- _ O
strategies -X- _ O
to -X- _ O
interfere -X- _ O
with -X- _ O
viral -X- _ O
RNA -X- _ O
translation -X- _ O
has -X- _ O
shown -X- _ O
efficacy -X- _ O
in -X- _ O
experimental -X- _ O
models -X- _ O
of -X- _ O
CNS -X- _ B-Patient
viral -X- _ I-Patient
disease. -X- _ I-Patient
Identifying -X- _ O
specific -X- _ O
molecular -X- _ O
targets -X- _ O
within -X- _ O
viral -X- _ O
replication -X- _ O
cycles -X- _ O
has -X- _ O
led -X- _ O
to -X- _ O
many -X- _ O
existing -X- _ O
antivirals -X- _ O
and -X- _ O
will -X- _ O
undoubtedly -X- _ O
continue -X- _ O
to -X- _ O
be -X- _ O
the -X- _ O
basis -X- _ O
of -X- _ O
future -X- _ O
drug -X- _ O
design. -X- _ O
A -X- _ O
promising -X- _ O
new -X- _ O
area -X- _ O
of -X- _ O
research -X- _ O
involves -X- _ O
therapies -X- _ O
based -X- _ O
on -X- _ O
enhanced -X- _ O
understanding -X- _ O
of -X- _ O
host -X- _ O
antiviral -X- _ O
immune -X- _ O
responses. -X- _ O
Toll-like -X- _ B-Outcome
receptor -X- _ I-Outcome
agonists -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
drugs -X- _ I-Outcome
that -X- _ I-Outcome
inhibit -X- _ I-Outcome
specific -X- _ I-Outcome
cytokines -X- _ I-Outcome
as -X- _ I-Outcome
well -X- _ I-Outcome
as -X- _ I-Outcome
interferon -X- _ I-Outcome
preparations -X- _ I-Outcome
have -X- _ I-Outcome
all -X- _ I-Outcome
shown -X- _ I-Outcome
potential -X- _ I-Outcome
therapeutic -X- _ I-Outcome
efficacy. -X- _ I-Outcome
Passive -X- _ O
transfer -X- _ O
of -X- _ O
virus- -X- _ O
specific -X- _ O
cytotoxic -X- _ O
T-lymphocytes -X- _ O
have -X- _ O
been -X- _ O
used -X- _ O
in -X- _ O
humans -X- _ O
and -X- _ O
may -X- _ O
provide -X- _ O
an -X- _ O
effective -X- _ O
therapies -X- _ O
for -X- _ O
some -X- _ O
herpesvirus -X- _ O
infections -X- _ O
and -X- _ O
potentially -X- _ O
for -X- _ O
progressive -X- _ O
multifocal -X- _ O
leukoencephalopathy. -X- _ O
Humanized -X- _ B-Intervention
monoclonal -X- _ I-Intervention
antibodies -X- _ I-Intervention
directed -X- _ O
against -X- _ O
specific -X- _ O
viral -X- _ O
proteins -X- _ O
have -X- _ O
been -X- _ O
developed -X- _ O
and -X- _ O
in -X- _ O
several -X- _ O
cases -X- _ O
evaluated -X- _ O
in -X- _ O
humans -X- _ O
in -X- _ O
settings -X- _ O
including -X- _ O
West -X- _ O
Nile -X- _ O
virus -X- _ O
and -X- _ O
HIV -X- _ O
infection -X- _ O
and -X- _ O
in -X- _ O
pre-exposure -X- _ O
prophylaxis -X- _ O
for -X- _ O
rabies -X- _ O
. -X- _ O

